Estonja - Estonjan - Ravimiamet

krka, d.d., novo mesto - ksülometasoliin+dekspantenool - ninasprei, lahus - 1mg+50mg 1ml 10ml 1tk

Estonja - Estonjan - Ravimiamet

stada arzneimittel ag - ksülometasoliin - ninasprei, lahus - 1mg 1ml 10ml 1tk

Estonja - Estonjan - Ravimiamet

glaxosmithkline dungarvan limited - ksülometasoliin - ninasprei, lahus - 1mg 1ml 10ml 1tk

Estonja - Estonjan - Ravimiamet

glaxosmithkline dungarvan limited - ksülometasoliin - ninatilgad, lahus - 0,5mg 1ml 10ml 1tk

Estonja - Estonjan - Ravimiamet

glaxosmithkline dungarvan limited - ksülometasoliin+dekspantenool - ninasprei, lahus - 1mg+50mg 1ml 10ml 1tk

Estonja - Estonjan - Ravimiamet

bayer uab - oksümetasoliin - ninasprei, lahus - 0,5mg 1ml 15ml 1tk

Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

bayer animal health gmbh - florfenicol, terbinafiin vesinikkloriid, mometasone furoaat - otologicals, kortikosteroidid ja antiinfectives koos - koerad - ravi ägeda koera otitis externa või ägeda ägenemised korduv otitis põhjustatud segatud infektsioonide suhtes vastuvõtlikud bakteritüvede tundlik florfenicol (staphylococcus pseudintermedius) ja seente suhtes tundlikud terbinafiin (malassezia pachydermatis).

Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - aneemia, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Estonja - Estonjan - Ravimiamet

mepha-investigacao, desenvolvimento e fabricacao farmaceutica, lda - ksülometasoliin - ninasprei, lahus - 0,5mg 1ml 10ml 1tk

Estonja - Estonjan - Ravimiamet

mepha-investigacao, desenvolvimento e fabricacao farmaceutica, lda - ksülometasoliin - ninasprei, lahus - 1mg 1ml 10ml 1tk